The global market for Cellular Immunotherapy was estimated at US$10.9 Billion in 2024 and is projected to reach US$33.6 Billion by 2030, growing at a CAGR of 20.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Cellular Immunotherapy market.
Segments: Therapy (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Other Therapies); Indication (B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication, Renal Cell Carcinoma Indication, Other Indications); End-Use (Hospitals End-Use, Cancer Institutes End-Use, Other End-Uses)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Cellular Immunotherapy Market - Key Trends & Drivers Summarized
How Is Cellular Immunotherapy Revolutionizing Cancer Treatment?
Cellular immunotherapy is transforming the landscape of cancer treatment by harnessing the body`s immune system to target and destroy malignant cells. Unlike traditional therapies such as chemotherapy and radiation, cellular immunotherapy leverages engineered immune cells, such as T-cells and natural killer (NK) cells, to provide a more targeted and potentially long-lasting response. Among the most notable advancements in this field are CAR-T cell therapies, which have shown remarkable success in treating blood cancers like leukemia and lymphoma. With the increasing focus on precision medicine, cellular immunotherapy is evolving to treat a wider range of conditions beyond oncology, including autoimmune disorders and infectious diseases. Advances in genetic engineering and biotechnology are enabling researchers to develop next-generation cell therapies that improve patient outcomes while minimizing adverse effects. As regulatory approvals expand and clinical trials yield promising results, the adoption of cellular immunotherapy is expected to rise significantly in the coming years.Why Is the Demand for Cellular Immunotherapy Increasing?
The increasing incidence of cancer and the limitations of conventional treatments are driving demand for cellular immunotherapy. Patients and healthcare providers are actively seeking alternative therapies that offer higher efficacy with fewer side effects. Moreover, the success of early CAR-T therapies has spurred a wave of investment in the development of new cell-based treatments, broadening the scope of immunotherapy applications. Additionally, growing advancements in gene editing technologies such as CRISPR and synthetic biology are enabling scientists to enhance the functionality and specificity of immune cells. The emergence of allogeneic or “off-the-shelf” cellular therapies is also a key factor driving market growth, as they offer scalable and cost-effective treatment solutions compared to patient-derived autologous therapies. These breakthroughs are not only improving patient accessibility but also making cellular immunotherapy a more viable and widespread treatment option.Which Regions Are Leading the Cellular Immunotherapy Market?
North America dominates the cellular immunotherapy market, fueled by strong R&D investments, a robust biotechnology sector, and early regulatory approvals. The United States, in particular, has led the commercialization of CAR-T therapies, with several FDA-approved treatments already in use for hematologic malignancies. The presence of leading pharmaceutical companies, research institutions, and advanced healthcare infrastructure further bolsters the region’s market leadership. Europe follows closely behind, with countries such as Germany, the UK, and France making significant strides in clinical research and therapy adoption. Meanwhile, the Asia-Pacific region is experiencing rapid growth due to increased government support, rising cancer prevalence, and expanding biotechnology capabilities in countries like China, Japan, and South Korea. Regulatory agencies in these regions are streamlining approval pathways, facilitating faster access to innovative cell-based treatments.What Are the Key Factors Driving Market Growth?
The growth in the Cellular Immunotherapy market is driven by several factors, including advancements in cell engineering, expanding indications beyond oncology, and increasing investment in biopharmaceutical R&D. The shift toward personalized medicine is also playing a crucial role, as cellular immunotherapy enables the development of patient-specific treatments tailored to individual genetic and immunological profiles. Moreover, ongoing efforts to enhance manufacturing scalability and reduce treatment costs are making these therapies more accessible. The rise of automation, AI-driven analytics, and bioprocess optimization is streamlining cell therapy production, ensuring higher efficiency and broader market adoption. As the field continues to evolve with novel technologies and expanded applications, cellular immunotherapy is expected to play a pivotal role in shaping the future of precision medicine and immuno-oncology.Report Scope
The report analyzes the Cellular Immunotherapy market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Therapy (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Other Therapies); Indication (B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication, Renal Cell Carcinoma Indication, Other Indications); End-Use (Hospitals End-Use, Cancer Institutes End-Use, Other End-Uses)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the CAR T Cell Therapy segment, which is expected to reach US$11.8 Billion by 2030 with a CAGR of a 24.2%. The Dendritic Cell Therapy segment is also set to grow at 21.0% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $3.0 Billion in 2024, and China, forecasted to grow at an impressive 28.2% CAGR to reach $8.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Cellular Immunotherapy Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cellular Immunotherapy Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Cellular Immunotherapy Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AbbVie Inc., Adicet Bio, Inc., Aduro Biotech, Inc., Agenus Inc., Amgen Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 41 Featured):
- AbbVie Inc.
- Adicet Bio, Inc.
- Aduro Biotech, Inc.
- Agenus Inc.
- Amgen Inc.
- Arcellx, Inc.
- AstraZeneca PLC
- BioNTech SE
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Celyad Oncology SA
- Dendreon Pharmaceuticals LLC
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc. (Kite Pharma)
- GlaxoSmithKline plc.
- Immunocore Holdings plc
- Iovance Biotherapeutics, Inc.
- Johnson & Johnson
- Kymab Ltd.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Adicet Bio, Inc.
- Aduro Biotech, Inc.
- Agenus Inc.
- Amgen Inc.
- Arcellx, Inc.
- AstraZeneca PLC
- BioNTech SE
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Celyad Oncology SA
- Dendreon Pharmaceuticals LLC
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc. (Kite Pharma)
- GlaxoSmithKline plc.
- Immunocore Holdings plc
- Iovance Biotherapeutics, Inc.
- Johnson & Johnson
- Kymab Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 386 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 10.9 Billion |
| Forecasted Market Value ( USD | $ 33.6 Billion |
| Compound Annual Growth Rate | 20.6% |
| Regions Covered | Global |
